Achievement of research milestone for immune program triggers milestone payment to Jnana and handover to Roche BOSTON, February 24, 2026 – Jnana Therapeutics,a clinical-stage biotechnology company leveraging its next-generation RAPID chemoproteomics platform, announces the achievement of a second pre-clinical milestone from its first collaboration agreement with Roche (SIX:RO, ROG; OTCQX: RHHBY). Jnana has advanced a… The post Jnana Therapeutics Announces Additional Pre-clinical Milestone Achieved UnderFirst Collaboration with Roche appeared first on Jnana Therapeutics .